Articles

IWTI Best Practices in Lung Cancer Navigation

Caring for the Caregiver in NSCLC

By Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T); Cathy Simmons, RN, BSN, ONN-CG(T); Lauren Welch, MSN, NP-C, AOCNP

Interview with the Innovators

Videos

Helping the patient’s caregiver understand their role in the NSCLC patient’s journey Read More ›

IWTI Best Practices in Lung Cancer Navigation

Common Questions from NSCLC Patients and Their Caregivers

By Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T); Cathy Simmons, RN, BSN, ONN-CG(T); Lauren Welch, MSN, NP-C, AOCNP

Interview with the Innovators

Videos

Addressing common questions from NSCLC patients and their caregivers Read More ›

IWTI Best Practices in Lung Cancer Navigation

Psychosocial Support for the NSCLC Patient

By Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T); Cathy Simmons, RN, BSN, ONN-CG(T); Lauren Welch, MSN, NP-C, AOCNP

Interview with the Innovators

Videos

Providing psychosocial support and counseling for NSCLC patients and their family Read More ›

IWTI Best Practices in Lung Cancer Navigation

Educating NSCLC Patients on Adverse Event Management

By Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T); Cathy Simmons, RN, BSN, ONN-CG(T); Lauren Welch, MSN, NP-C, AOCNP

Interview with the Innovators

Videos

Educating patients about cancer- and treatment-related side effect management Read More ›

Using the FDA Adverse Event Reporting System to Find Links Between Interstitial Lung Disease and CDK4/6 Inhibitors

Breast Cancer

Web Exclusives

Evaluation of real-world reports will help with the early clinical assessment of interstitial lung disease potentially associated with CDK4/6 inhibitors. Read More ›

Quality of Life in Breast Cancer Survivors Using an Electronic Home-Based Symptom Management and Mindfulness Training Program

Breast Cancer

Web Exclusives

An electronic home-based multidimensional cancer survivorship program did not clearly affect outcomes in women with breast cancer, although a positive impact was revealed in interviews. Read More ›

Impact of a CDK4/6 Inhibitor plus Fulvestrant on Overall Survival in Patients with Breast Cancer

Breast Cancer

Web Exclusives

Pooled analyses of overall survival shows the addition of CDK inhibitors to fulvestrant confers a consistent survival benefit in patients with breast cancer. Read More ›

Persistent Race-Associated Disparities in Genetic Testing of Patients with Breast Cancer

Breast Cancer

Web Exclusives

As mutation-associated targeted therapies are identified, it is critical to address genetic testing disparities. Read More ›

Differences in Toxicity Profiles and Impact on CDK4/6 Inhibitor Treatment Choice

Breast Cancer

Web Exclusives

CDK4/6 inhibitors have similar efficacy; therefore, clinicians should consider toxicity when selecting an optimal therapeutic approach. Read More ›